Machine Learning for Patient Forecasting and Site Selection

Various neurodegenerative processes result in the development of diseases like Alzheimer’s (AD), Parkinson’s (PD), amyotrophic lateral sclerosis (ALS), and, arguably, multiple sclerosis (MS). Despite years of research, drug discovery initiatives, and promising clinical trials, these diseases remain incurable. But recent studies have suggested common mechanisms underlying these pathologies. Atypical protein assembly resulting in plaque formation is a common pathological finding in both AD and PD, while neuronal death is a primary (ALS) or secondary (MS) hallmark of the disease. For a detailed look at the mechanisms that drive an array of neurodegenerative diseases, The Scientist is bringing together a panel of experts to share their research, discuss current therapeutic approaches, and offer their insights. Come engage with our panel and get the answers you seek.

Increasingly, the conventional ways of maintaining pharma equipment call for a digital alternative. Non-wear-based failures such as operating excursion and changes in operation plans make up to 80% of equipment failures.

This webinar will benefit executives at Biotech and Pharmaceutical companies interested in learning more about 505(b)(2) drug development and how to save time and money while maximizing the value of their drug development program.

Discovering new “drug-like” and synthetically viable compounds via artificial intelligence (AI) is of great interest to medicinal chemists.